Premarket Decliner
EWTX Edgewise Therapeutics35.21+0.38+1.1%
Premarket:26.00-9.21 (-26.2%)
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
PRNewswireTue, 16-Jun 7:00 AM
EWTX Edgewise Therapeutics23.86+0.92 (+4.0%)
EWTX Edgewise Therapeutics20.41-5.14 (-20.1%)
EWTX Edgewise Therapeutics23.67+2.52 (+11.9%)
EWTX Edgewise Therapeutics24.07+0.45 (+1.9%)
EWTX Edgewise Therapeutics23.95+0.52 (+2.2%)